Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.

@article{Ang2014RandomizedPI,
  title={Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.},
  author={K. Kian Ang and Qiang Zhang and David I. Rosenthal and Phuc Felix Nguyen-Tan and Eric J Sherman and Randal S. Weber and J. M. Galvin and James A. Bonner and Jonathan Harris and A El-naggar and Maura L. Gillison and Richard C. K. Jordan and Andre A. Konski and W. L. Thorstad and Andy M. Trotti and J J Beitler and Adam Seth Garden and William J. Spanos and Sue S Yom and Rita Susan Axelrod},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2014},
  volume={32 27},
  pages={
          2940-50
        }
}
PURPOSE Combining cisplatin or cetuximab with radiation improves overall survival (OS) of patients with stage III or IV head and neck carcinoma (HNC). Cetuximab plus platinum regimens also increase OS in metastatic HNC. The Radiation Therapy Oncology Group launched a phase III trial to test the hypothesis that adding cetuximab to the radiation-cisplatin platform improves progression-free survival (PFS). PATIENTS AND METHODS Eligible patients with stage III or IV HNC were randomly assigned to… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 34 times over the past 90 days. VIEW TWEETS
132 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 132 extracted citations

Similar Papers

Loading similar papers…